Evaluating whether Niagen Bioscience (trading under the NASDAQ ticker NAGE, formerly ChromaDex) represents a good investment requires careful fundamental analysis of its revenue growth, cash position, and profitability milestones in the bioscience sector. The company benefits from a strong intellectual property portfolio, rising global demand for healthy-aging products, and expanding retail partnerships. However, because small-cap biotechnology and supplement equities carry inherent market volatility, investors should review quarterly financial reports and consult a financial advisor.